CTOs on the Move

Caris Life Sciences

www.carisls.com

 
Caris Life Sciences® (Caris) is a molecular science company developing and delivering technologies to revolutionize healthcare. The Company`s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers improve outcomes and save lives. Caris is also advancing precision medicine through advanced artificial intelligence (AI) and machine learning algorithms. Leveraging the Company`s proprietary AI analytics engine, DEAN™, across its extensive catalog of molecular intelligence and clinical outcomes data, Caris is actively developing a better understanding of the molecular mechanisms of cancer in ways never before possible. This information provides ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.carisls.com
  • 750 West John Carpenter Freeway Suite 800
    Irving, TX USA 75039
  • Phone: 866.771.8946

Executives

Name Title Contact Details

Funding

Caris Life Sciences raised $150M on 10/01/2018
Caris Life Sciences raised $235M on 10/27/2020
Caris Life Sciences raised $75M on 10/27/2020
Caris Life Sciences raised $830M on 05/11/2021

Similar Companies

Mascoma Corporation

Mascoma Corporation is a Brighton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angstrom Scientific

Angstrom Scientific is a Ramsey, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADS

ADS is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Champions Oncology

Champions Oncology is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.